HC Wainwright Estimates Agenus' Q3 Earnings (NASDAQ:AGEN)

Key Points

• HC Wainwright cut Agenus’ Q3 2026 EPS estimate to a loss of $0.01 from a prior forecast of $0.05, while maintaining a Buy rating and $25 price target. The firm also projects continued losses through 2030.
• Agenus reported a Q2 loss of $0.01 per share, missing the $0.05 consensus estimate, although quarterly revenue of $34.52 million exceeded expectations of $34.00 million.
• Agenus shares opened at $6.90, up 1.0%, with institutional investors owning 61.46% of the stock. Analyst sentiment is mixed overall, with a consensus Hold rating and average price target of $19.50.

Agenus Inc. (NASDAQ:AGEN - Free Report) - Equities researchers at HC Wainwright cut their Q3 2026 earnings per share estimates for shares of Agenus in a research note issued to investors on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will post earnings of ($0.01) per share for the quarter, down from their previous estimate of $0.05. HC Wainwright has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for Agenus' current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Agenus' Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.37) EPS, FY2027 earnings at ($0.43) EPS, FY2028 earnings at ($0.68) EPS, FY2029 earnings at ($0.71) EPS and FY2030 earnings at ($0.37) EPS.

Agenus (NASDAQ:AGEN - Get Free Report) last released its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.06). Agenus had a negative return on equity of 45.12% and a net margin of 69.33%.The firm had revenue of $34.52 million for the quarter, compared to analyst estimates of $34.00 million.

AGEN has been the topic of several other reports. B. Riley Financial reiterated a "buy" rating and issued a $14.00 price target (up from $8.00) on shares of Agenus in a research note on Thursday, July 30th. Zacks Research cut Agenus from a "strong-buy" rating to a "hold" rating in a report on Monday, May 11th. Weiss Ratings upgraded Agenus from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, August 7th. Finally, Wall Street Zen raised Agenus from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Agenus has an average rating of "Hold" and a consensus price target of $19.50.

Agenus Stock Up 1.0%

Shares of AGEN stock opened at $6.90 on Thursday. Agenus has a 12 month low of $2.71 and a 12 month high of $8.85. The company's fifty day simple moving average is $4.69 and its 200-day simple moving average is $3.89. The firm has a market cap of $310.64 million, a PE ratio of 2.67 and a beta of 1.41.

Institutional Investors Weigh In On Agenus

A number of large investors have recently added to or reduced their stakes in AGEN. EP Wealth Advisors LLC bought a new position in shares of Agenus in the fourth quarter valued at about $31,000. R Squared Ltd acquired a new position in Agenus in the 4th quarter valued at about $41,000. Redwood Family Wealth LLC bought a new position in Agenus in the 4th quarter valued at about $44,000. Quadrature Capital Ltd bought a new position in Agenus in the 4th quarter valued at about $54,000. Finally, Squarepoint Ops LLC bought a new position in Agenus in the 3rd quarter valued at about $54,000. Institutional investors own 61.46% of the company's stock.

Key Stories Impacting Agenus

Here are the key news stories impacting Agenus this week:

• Positive Sentiment: HC Wainwright raised its Q3 2026 EPS forecast to $0.05 from $0.03, increased its Q4 forecast to $0.05 from $0.01, and improved its FY2026 loss estimate to $0.15 per share from $0.22. The firm maintained a Buy rating and a $25 price target for the Q3 update, while other notes cited a $30 target. These revisions suggest better near-term earnings expectations and may be supporting investor optimism.
• Positive Sentiment: Agenus expanded its board from six to seven members and appointed Rom... as a new director. The addition could strengthen the company’s governance and strategic oversight. Agenus Strengthens Board With New Director Appointment
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the figures are internally inconsistent and show no measurable short position, they provide little reliable information about trading pressure.
• Negative Sentiment: HC Wainwright lowered its longer-term EPS forecasts for FY2027 through FY2030, including FY2027 to a $0.19 loss from $0.16, FY2028 to a $0.49 loss from $0.43, FY2029 to a $0.58 loss from $0.51, and FY2030 to a $0.31 loss from $0.26. The revisions indicate that profitability remains uncertain despite the improved 2026 outlook.

Agenus Company Profile

Agenus, Inc NASDAQ: AGEN is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system's response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus' pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source